rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.14412/1995-4484-2017-446-448rsp-2419Research ArticleКЛИНИЧЕСКОЕ НАБЛЮДЕНИЕCLINICAL OBSERVATIONSИндуцированный инфликсимабом волчаночно-подобный синдром у больной ревматоидным артритом (описание случая): случайность или закономерность?INFLIXIMAB-INDUCED LUPUS-LIKE SYNDROME IN A FEMALE PATIENT WITH RHEUMATOID ARTHRITIS (A CASE REPORT): AN ACCIDENT OR REGULARITY?МуравьевЮ. В.MuravyevYu. V.

115522 Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

murawyu@mail.ruЛебедеваВ. В.LebedevaV. V.

115522 Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

АламанкинаС. Ю.AlamankinaS. Yu.

115522 Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation201729092017554446448Copyright © Муравьев Ю.В., Лебедева В.В., Аламанкина С.Ю., 20172017Муравьев Ю.В., Лебедева В.В., Аламанкина С.Ю.Muravyev Y.V., Lebedeva V.V., Alamankina S.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/2419

В статье описывается случай развития волчаночно-подобного синдрома, индуцированного инфликсимабом, у больной ревматоидным артритом, с обсуждением возможных причин возникновения такой патологии.

The paper describes a case of infliximab-induced lupus-like syndrome in a female patient with rheumatoid arthritis and discusses the possible causes of this pathology.

ревматоидный артритинфликсимабволчаночно-подобный синдромrheumatoid arthritisinfliximablupus-like syndromeReferencesWetter DA, Davis MDP. Lupus-like syndrome attributable to antitumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic. Mayo Clinic Proc. 2009 Nov;84(11):979-84.doi: 10.1016/S0025-6196(11)60668-XWetter DA, Davis MDP. Lupus-like syndrome attributable to antitumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic. Mayo Clinic Proc. 2009 Nov;84(11):979-84.doi: 10.1016/S0025-6196(11)60668-XDesai SB, Furst DE. Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol. 2006;20:757-90. doi: 10.1016/j.berh.2006.06.002Desai SB, Furst DE. Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol. 2006;20:757-90. doi: 10.1016/j.berh.2006.06.002Hoffman BJ. Sensitivity to sulfadiazine resembling acute disseminated lupus erythematosus. Arch Dermatol Syph. 1945;51:190-2. doi: 10.1001/archderm.1945.01510210032007Hoffman BJ. Sensitivity to sulfadiazine resembling acute disseminated lupus erythematosus. Arch Dermatol Syph. 1945;51:190-2. doi: 10.1001/archderm.1945.01510210032007Borchers AT, Keen CL, Gershwin ME. Drug-induced lupus. Ann N Y Acad Sci. 2007;1108:166-82. doi: 10.1196/annals.1422.019Borchers AT, Keen CL, Gershwin ME. Drug-induced lupus. Ann N Y Acad Sci. 2007;1108:166-82. doi: 10.1196/annals.1422.019Vasoo S. Drug-induced lupus: an update. Lupus. 2006;15:757-61. doi: 10.1177/0961203306070000Vasoo S. Drug-induced lupus: an update. Lupus. 2006;15:757-61. doi: 10.1177/0961203306070000Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271-7. doi: 10.1002/art.1780251101Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271-7. doi: 10.1002/art.1780251101Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725. doi: 10.1002/art.1780400928Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725. doi: 10.1002/art.1780400928Williams EL, Gadola S, Edwards CJ. Anti-TNF-induced lupus. Rheumatology (Oxford). 2009;48:716-20. doi: 10.1093/rheumatology/kep080Williams EL, Gadola S, Edwards CJ. Anti-TNF-induced lupus. Rheumatology (Oxford). 2009;48:716-20. doi: 10.1093/rheumatology/kep080Charles PJ, Smeenk RJ, De Jong J, et al. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum. 2000;43:2383-90. doi: 10.1002/15290131(200011)43:11<2383::AID-ANR2>3.0.CO;2-DCharles PJ, Smeenk RJ, De Jong J, et al. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum. 2000;43:2383-90. doi: 10.1002/15290131(200011)43:11<2383::AID-ANR2>3.0.CO;2-DFavalli EG, Sinigaglia L, Varenna M, Arnoldi C. Drug-induced lupus following treatment with infliximab in rheumatoid arthritis. Lupus. 2002;11:753-5. doi: 10.1191/0961203302lu236crFavalli EG, Sinigaglia L, Varenna M, Arnoldi C. Drug-induced lupus following treatment with infliximab in rheumatoid arthritis. Lupus. 2002;11:753-5. doi: 10.1191/0961203302lu236crCosta MF, Said NR, Zimmermann B. Drug-induced lupus due to anti-tumor necrosis factor alpha agents. Semin Arthritis Rheum. 2008;37:381-7. doi: 10.1016/j.semarthrit.2007.08.003Costa MF, Said NR, Zimmermann B. Drug-induced lupus due to anti-tumor necrosis factor alpha agents. Semin Arthritis Rheum. 2008;37:381-7. doi: 10.1016/j.semarthrit.2007.08.003Klapman JB, Ene-Stroscu D, Becker MA, Hanauer SB. A lupuslike syndrome associated with infiximab therapy. Inflamm Bowel Dis. 2003;9:176-8. doi: 10.1097/00054725-00305000-00005Klapman JB, Ene-Stroscu D, Becker MA, Hanauer SB. A lupuslike syndrome associated with infiximab therapy. Inflamm Bowel Dis. 2003;9:176-8. doi: 10.1097/00054725-00305000-00005Sarzi-Puttini P, Ardizzone S, Manzionna G, et al. Infliximabinduced lupus in Crohn's disease: a case report. Dig Liver Dis. 2003;35:814-7. doi: 10.1016/S1590-8658(03)00448-1Sarzi-Puttini P, Ardizzone S, Manzionna G, et al. Infliximabinduced lupus in Crohn's disease: a case report. Dig Liver Dis. 2003;35:814-7. doi: 10.1016/S1590-8658(03)00448-1Bleumink GS, ter Borg EJ, Ramselaar CG, Strickler BH. Etanercept-induced subacute cutaneous lupus erythemaotosus. Rheumatology. 2001;40:1317-9. doi: 10.1093/rheumatology/40.11.1317Bleumink GS, ter Borg EJ, Ramselaar CG, Strickler BH. Etanercept-induced subacute cutaneous lupus erythemaotosus. Rheumatology. 2001;40:1317-9. doi: 10.1093/rheumatology/40.11.1317Shakoor N, Michalska M, Harris CA, Block JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet. 2002;359:579-80. doi: 10.1016/S0140-6736(02)07714-0Shakoor N, Michalska M, Harris CA, Block JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet. 2002;359:579-80. doi: 10.1016/S0140-6736(02)07714-0Carlson E, Rothfield N. Etanercept-induced lupus like syndrome in a patient with rheumatoid arthritis. Arthritis Rheum. 2003;48:1165-6. doi: 10.1002/art.11033Carlson E, Rothfield N. Etanercept-induced lupus like syndrome in a patient with rheumatoid arthritis. Arthritis Rheum. 2003;48:1165-6. doi: 10.1002/art.11033Cairns AP, Duncan MK, Hinder AE, Taggart AJ. New onset systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritis. Ann Rheum Dis. 2002;61:1031-2. doi: 10.1136/ard.61.11.1031Cairns AP, Duncan MK, Hinder AE, Taggart AJ. New onset systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritis. Ann Rheum Dis. 2002;61:1031-2. doi: 10.1136/ard.61.11.1031Swale VJ, Perrett CM, Denton CP, et al. Etanercept-induced systemic lupus erythematosus. Clin Exp Dermatol. 2003;28:604-7. doi: 10.1046/j.1365-2230.2003.01411.xSwale VJ, Perrett CM, Denton CP, et al. Etanercept-induced systemic lupus erythematosus. Clin Exp Dermatol. 2003;28:604-7. doi: 10.1046/j.1365-2230.2003.01411.xKang M-J, Lee Y-H, Lee J. Etanercept-induced systemic lupus erythematosus in a patient with rheumatoid arthritis. J Korean Med Sci. 2006;21:946-9. doi: 10.3346/jkms.2006.21.5.946Kang M-J, Lee Y-H, Lee J. Etanercept-induced systemic lupus erythematosus in a patient with rheumatoid arthritis. J Korean Med Sci. 2006;21:946-9. doi: 10.3346/jkms.2006.21.5.946Haake H, Kä neke J, Amann K, et al. Development of systemic lupus erythematosus with focal proliferative lupus nephritis during anti-TNF-alpha therapy for psoriatic arthritis. Med Klin. 2007;102:852-7. doi: 10.1007/s00063-007-1104-6Haake H, Kä neke J, Amann K, et al. Development of systemic lupus erythematosus with focal proliferative lupus nephritis during anti-TNF-alpha therapy for psoriatic arthritis. Med Klin. 2007;102:852-7. doi: 10.1007/s00063-007-1104-6Van Rijthoven AWAM, Bijlsma JWJ, Canninga-Van Dijk M, et al. Onset of systemic lupus erythematosus after conversion of infliximab to adalimumab treatment in rheumatoid arthritis with a preexisting anti-dsDNA antibody level. Rheumatology. 2006;45:1317- 9. doi: 10.1093/rheumatology/kel227Van Rijthoven AWAM, Bijlsma JWJ, Canninga-Van Dijk M, et al. Onset of systemic lupus erythematosus after conversion of infliximab to adalimumab treatment in rheumatoid arthritis with a preexisting anti-dsDNA antibody level. Rheumatology. 2006;45:1317- 9. doi: 10.1093/rheumatology/kel227Schiff MH, Burmester GR, Kent JD, et al. Safety analyses of adalimumab (HUMIRA)in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis. 2006;65:889-94. doi: 10.1136/ard.2005.043166Schiff MH, Burmester GR, Kent JD, et al. Safety analyses of adalimumab (HUMIRA)in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis. 2006;65:889-94. doi: 10.1136/ard.2005.043166De Bant M, Sibilia J, Le Loet X, et al. Systemic lupus erythematosus induced by anti- tumor necrosis factor alpha therapy: a French survey. Arthritis Res Ther. 2005;7(3):R545-51. doi: 10.1186/ar1715De Bant M, Sibilia J, Le Loet X, et al. Systemic lupus erythematosus induced by anti- tumor necrosis factor alpha therapy: a French survey. Arthritis Res Ther. 2005;7(3):R545-51. doi: 10.1186/ar1715Ramos-Casal M, Brito-Zeron P, Munoz S, et al. Autoimmune diseases induced by TNF- targeted therapies. Analysis of 233 cases. Medicine. 2007;86:242-51. doi: 10.1097/MD.0b013e3181441a68Ramos-Casal M, Brito-Zeron P, Munoz S, et al. Autoimmune diseases induced by TNF- targeted therapies. Analysis of 233 cases. Medicine. 2007;86:242-51. doi: 10.1097/MD.0b013e3181441a68Thornhill J, Watson KD, Lord PA, et al. Drug-induced lupus in patients with inflammatory arthritis treated with TNF blocking agents: results from the BSR Biologics Register. BSR Abstracts. 2008.Thornhill J, Watson KD, Lord PA, et al. Drug-induced lupus in patients with inflammatory arthritis treated with TNF blocking agents: results from the BSR Biologics Register. BSR Abstracts. 2008.Jacob CO, McDevitt HO. Tumour necrosis factor-alpha in urine autoimmune 'lupus' nephritis. Nature. 1988;331:356-8. doi: 10.1038/331356a0Jacob CO, McDevitt HO. Tumour necrosis factor-alpha in urine autoimmune 'lupus' nephritis. Nature. 1988;331:356-8. doi: 10.1038/331356a0Kontoyiannis D, Kollias G. Accelerated autoimmunity and lupus nephritis in NZB mice with an engineered heterozygous deficiency in tumour necrosis factor. Eur J Immunol. 2000;30:2038-47. doi: 10.1002/1521-4141(200007)30:7<2038::AIDIMMU2038>3.0.CO;2-KKontoyiannis D, Kollias G. Accelerated autoimmunity and lupus nephritis in NZB mice with an engineered heterozygous deficiency in tumour necrosis factor. Eur J Immunol. 2000;30:2038-47. doi: 10.1002/1521-4141(200007)30:7<2038::AIDIMMU2038>3.0.CO;2-KGordon C, Ranges GE, Greenspan JS, Wofsy D. Chronic therapy with recombinant tumour necrosis factor-alpha in autoimmune NZB/NZW F1 mice. Clin Immunol Immunopathol. 1989;52:421- 34. doi: 10.1016/0090-1229(89)90157-8Gordon C, Ranges GE, Greenspan JS, Wofsy D. Chronic therapy with recombinant tumour necrosis factor-alpha in autoimmune NZB/NZW F1 mice. Clin Immunol Immunopathol. 1989;52:421- 34. doi: 10.1016/0090-1229(89)90157-8Singh VK, Mehrotra S, Agarwal SS. The paradigm of Th1 and Th2 cytokines: its relevance to autoimmunity and allergy. Immunol Res. 1999;20:147-61. doi: 10.1007/BF02786470Singh VK, Mehrotra S, Agarwal SS. The paradigm of Th1 and Th2 cytokines: its relevance to autoimmunity and allergy. Immunol Res. 1999;20:147-61. doi: 10.1007/BF02786470Romagnani S. Th1/Th2 cells. Inflamm Bowel Dis. 1999;5:285-94. doi: 10.1097/00054725-199911000-00009Romagnani S. Th1/Th2 cells. Inflamm Bowel Dis. 1999;5:285-94. doi: 10.1097/00054725-199911000-00009Bickerstaff MC, Botto M, Hutchinson WL, et al. Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat Med. 1999;5:694-7. doi: 10.1038/9544Bickerstaff MC, Botto M, Hutchinson WL, et al. Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat Med. 1999;5:694-7. doi: 10.1038/9544Lorenz HM, Herrmann M, Winkler T, et al. Role of apoptosis in autoimmunity. Apoptosis. 2000;5:443-9. doi: 10.1023/A:1009692902805Lorenz HM, Herrmann M, Winkler T, et al. Role of apoptosis in autoimmunity. Apoptosis. 2000;5:443-9. doi: 10.1023/A:1009692902805Erikkson C, Engstrand S, Sundqvist K-G, Rantapaat-Dahlqvist S. Autoantibody formationin patients with rheumatoid arthritis treated with anti-TNF. Ann Rheum Dis. 2005;64:403-7. doi: 10.1136/ard.2004.024182Erikkson C, Engstrand S, Sundqvist K-G, Rantapaat-Dahlqvist S. Autoantibody formationin patients with rheumatoid arthritis treated with anti-TNF. Ann Rheum Dis. 2005;64:403-7. doi: 10.1136/ard.2004.024182Zheng L, Fisher G, Miller R, et al. Induction of apoptosis in mature T cells by tumor necrosis factor. Nature. 1995;377:348-51. doi: 10.1038/377348a0Zheng L, Fisher G, Miller R, et al. Induction of apoptosis in mature T cells by tumor necrosis factor. Nature. 1995;377:348-51. doi: 10.1038/377348a0Sarzi-Puttini P, Atzeni F, Capsoni F, et al. Drug-induced lupus erythematosus. Autoimmunity. 2005;38:507-18. doi: 10.1080/08916930500285857Sarzi-Puttini P, Atzeni F, Capsoni F, et al. Drug-induced lupus erythematosus. Autoimmunity. 2005;38:507-18. doi: 10.1080/08916930500285857D'Auria F, Rovere-Querini P, Giazzon M, et al. Accumulation of plasma nucleosomes upon treatment with anti-tumour necrosis factor-α antibodies. J Intern Med. 2004;255:409-18. doi: 10.1111/j.1365-2796.2003.01298.xD'Auria F, Rovere-Querini P, Giazzon M, et al. Accumulation of plasma nucleosomes upon treatment with anti-tumour necrosis factor-α antibodies. J Intern Med. 2004;255:409-18. doi: 10.1111/j.1365-2796.2003.01298.xBenucci M, Saviola G, Baiardi P, et al. Anti-nucleosome antibodies as prediction factor of development of autoantibodies during therapy with three different TNF blocking agents in rheumatoid arthritis. Clin Rheumatol. 2008;27:91-5. doi: 10.1007/s10067-007-0728-5Benucci M, Saviola G, Baiardi P, et al. Anti-nucleosome antibodies as prediction factor of development of autoantibodies during therapy with three different TNF blocking agents in rheumatoid arthritis. Clin Rheumatol. 2008;27:91-5. doi: 10.1007/s10067-007-0728-5

The authors declare that there are no conflicts of interest present.